Table 1 Cause-specific survival: invasive Melanoma in Queensland (1995–2008, follow-up to 2010)
From: Prognostic survival model for people diagnosed with invasive cutaneous melanoma
| Â | Total | 1 year survival | 5 year survival | 10 year survival |
|---|---|---|---|---|
Total | 28,654 (100%) | 99.1 | 95.0 | 92.6 |
Gender | Â | Â | Â | Â |
 Male | 16,269 (57%) | 98.9 | 93.8 | 90.8 |
 Female | 12,385 (43%) | 99.4 | 96.5 | 94.8 |
Age group (years)a | Â | Â | Â | Â |
 20-39 | 4,958 (17%) | 99.8 | 97.4 | 96.1 |
 40-59 | 10,814 (38%) | 99.5 | 96.5 | 94.4 |
 60-69 | 5,405 (19%) | 99.1 | 94.6 | 91.7 |
 70-79 | 5,006 (17%) | 98.7 | 92.0 | 87.9 |
 80-89 | 2,471 (9%) | 97.5 | 88.6 | 85.2 |
Thicknessa | Â | Â | Â | Â |
 <=0.50 mm | 12,641 (44%) | 100 | 99.6 | 99.0 |
 0.51-1.00 | 8,107 (28%) | 99.9 | 97.9 | 96.2 |
 1.01-1.50 | 2,487 (9%) | 99.2 | 93.1 | 88.3 |
 1.51-2.00 | 1,386 (5%) | 98.8 | 87.9 | 80.3 |
 2.01-4.00 | 2,234 (8%) | 97.3 | 79.6 | 70.8 |
 4.01+ | 1,170 (4%) | 92.9 | 67.8 | 61.4 |
 Unknownb | 629 (2%) | 91.5 | 82.6 | 78.6 |
Body site | Â | Â | Â | Â |
 Scalp | 565 (2%) | 96.2 | 78.8 | 69.3 |
 Face/Lip/Eyelid | 2,221 (8%) | 99.0 | 94.5 | 90.4 |
 Ear/Neck | 1,741 (6%) | 98.9 | 93.4 | 90.6 |
 Chest/Axilla | 1,435 (5%) | 99.2 | 96.0 | 94.0 |
 Abdomen + Hip | 791 (3%) | 98.7 | 93.7 | 90.7 |
 Back/Buttocks | 8,046 (28%) | 99.5 | 95.2 | 92.8 |
 Upper arm/Forearm/Hand/Finger/sb.hand | 3,644 (13%) | 99.5 | 96.6 | 95.4 |
 Foot/sb. foot/heel/toec | 384 (1%) | 97.4 | 87.7 | 79.6 |
 Thigh/leg/ankle | 5,961 (21%) | 99.5 | 96.5 | 94.7 |
 Shoulder | 2,452 (9%) | 99.5 | 96.0 | 93.7 |
 Unknownb | 1,414 (5%) | 96.4 | 92.0 | 90.2 |
Morphology | Â | Â | Â | Â |
 Superficial spreading melanoma | 16,229 (57%) | 99.7 | 97.3 | 95.7 |
 Nodular melanoma | 2,415 (8%) | 96.2 | 79.0 | 73.1 |
 Malignant melanoma in junctional naevus | 654 (2%) | 99.7 | 98.0 | 97.1 |
 Lentigo Maligna melanoma | 1,688 (6%) | 99.8 | 97.4 | 95.6 |
 Acral lentiginous melanoma | 144 (<1%) | 97.9 | 85.5 | 80.2 |
 Other specified melanoma | 1,015 (4%) | 97.5 | 87.6 | 79.8 |
 Malignant melanoma NOS | 6,509 (23%) | 98.9 | 95.2 | 92.7 |
Ulceration | Â | Â | Â | Â |
 No ulceration | 17,110 (60%) | 99.7 | 97.3 | 95.5 |
 Known ulceration | 2,627 (9%) | 95.4 | 77.0 | 70.7 |
 No mention on pathologyb | 8,917 (31%) | 99.1 | 95.5 | 93.1 |
Clarks level | Â | Â | Â | Â |
 Into papillary dermis | 15,488 (54%) | 99.9 | 99.4 | 98.5 |
 Filling papillary dermis | 6,164 (22%) | 99.6 | 95.3 | 92.7 |
 Into reticular dermis | 5,584 (19%) | 98.0 | 86.6 | 80.3 |
 Into subcutaneous fat | 715 (3%) | 93.4 | 70.0 | 60.7 |
 Unknownb | 703 (2%) | 92.4 | 80.9 | 73.9 |
Positive nodes | Â | Â | Â | Â |
 None | 28,421 (99%) | 99.3 | 95.4 | 93.0 |
 At least one | 229 (<1%) | 75.2 | 43.6 | 37.5 |
Metastasis | Â | Â | Â | Â |
 No | 28,506 (99%) | 99.3 | 95.3 | 92.9 |
 Yes | 148 (<1%) | 68.7 | 39.4 | 27.6 |